WallStreetZenWallStreetZen

NASDAQ: SBFM
Sunshine Biopharma Inc Stock Ownership - Who owns Sunshine Biopharma?

Insider buying vs selling

Have Sunshine Biopharma Inc insiders been buying or selling?
Buy
Sell
NameRoleDateSharesPriceValue
Steve N. SlilatyChief Executive Officer2024-03-04100,000$0.10
$10.00kBuy
Steve N. SlilatyChief Executive Officer2024-02-0820,000$0.10
$2.00kBuy

1 of 1

SBFM insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when SBFM insiders and whales buy or sell their stock.

SBFM Shareholders

What type of owners hold Sunshine Biopharma Inc stock?
Institutional
Insider
Retail
NameHoldSharesValueType
Renaissance Technologies LLC463.63%4,610,900$4.29MInstitution
Malek Chamoun372.04%3,700,000$3.44MInsider
Citadel Advisors LLC55.35%550,514$511.98kInstitution
Bridgeway Capital Management LLC28.77%286,100$266.07kInstitution
Camille Sebaaly17.54%174,465$162.25kInsider
Steve N. Slilaty13.07%130,000$120.90kInsider
Jane Street Group LLC8.81%87,610$81.48kInstitution
Royal Bank Of Canada6.54%65,000$60.45kInstitution
Xtx Topco Ltd5.40%53,722$49.96kInstitution
Geode Capital Management LLC2.03%20,179$18.77kInstitution

1 of 3

SBFM vs Pharmaceutical Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
SBFM58.83%41.17%Net BuyingNet Buying
SXTC0.39%0.00%
AKAN1.20%0.00%
PRFX9.63%0.00%
LSDI6.20%93.80%

Sunshine Biopharma Stock Ownership FAQ

Who owns Sunshine Biopharma?

Sunshine Biopharma (NASDAQ: SBFM) is owned by 575.32% institutional shareholders, 402.65% Sunshine Biopharma insiders, and 0.00% retail investors. Malek Chamoun is the largest individual Sunshine Biopharma shareholder, owning 3.70M shares representing 372.04% of the company. Malek Chamoun's Sunshine Biopharma shares are currently valued at $3.44M.

If you're new to stock investing, here's how to buy Sunshine Biopharma stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.